Ranolazine for treatment of chronic stable angina
Metadata[+] Show full item record
Ranolazine (Ranexa®) was approved by the US Food and Drug Administration for the treatment of patients with chronic stable angina in combination with amlodipine, beta-blockers, or nitrates in January 2006. Randomized trials have confirmed that ranolazine is effective for decreasing symptoms of angina without effecting blood pressure or heart rate, but the drug has not been shown to significantly reduce the risk of cardiovascular death or recurrent ischemia.
Evidence Based Practice 11(5): 10+.